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AbstrAct
Prostate cancer is a highly heterogeneous disease and the clinical outcome is 
varying. While current prognostic tools are regarded insufficient, there is a critical 
need for markers that would aid prognostication and patient risk-stratification. Heat 
shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a 
driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, 
unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression 
datasets on prostate cancer. Clinical validation was performed on tissue microarrays 
from independent cohorts: one constructed from radical prostatectomies from 478 
patients with long term follow-up, and another comprising of regionally advanced 
to distant metastatic samples. Associations with clinical variables and disease 
outcomes were investigated. Increased nuclear HSF1 expression correlated with 
disease advancement and aggressiveness and was, independently from established 
clinicopathological variables, predictive of both early initiation of secondary therapy 
and poor disease-specific survival. In a joint model with the clinical Cancer of the 
Prostate Risk Assessment post-Surgical (CAPRA-S) score, nuclear HSF1 remained 
a predictive factor of shortened disease-specific survival. The results suggest that 
nuclear HSF1 expression could serve as a novel prognostic marker for patient risk-
stratification on disease progression and survival after radical prostatectomy. 
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IntroductIon
Prostate cancer is one of the most commonly 
diagnosed male cancer in Western countries, and 
worldwide approximately one million new prostate cancer 
cases are diagnosed each year [1]. The clinical course is 
highly variable; although primary prostate cancer often 
remains indolent, a considerable proportion progresses 
into castration-resistant prostate cancer. Advanced prostate 
cancer can rapidly metastasize both locally to the lymph 
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nodes and distantly to bone, central nervous system, lung 
or other organs, and at this stage, despite therapeutic 
advances, there are still no curative treatments available 
and the metastasizing phenotype is lethal. 
For localized prostate cancer a common treatment 
is radical prostatectomy. The most widely used tool to 
evaluate prognosis after primary treatment is Gleason 
grading, which is based on the glandular pattern of the 
tumor. However, accurate risk-stratification throughout 
the whole range of patients remains difficult, particularly 
for intermediate Gleason score tumors that often represent 
the vast majority of patients [2–4]. In addition, tumors 
with similar histological patterns can exhibit different 
clinical outcomes [5, 6]. Although Gleason grading was 
recently updated to a grade group system [7], and is being 
used in combination with other established parameters, 
foremost tumor stage and prostate-specific antigen (PSA), 
current prognostication is insufficient and accurate risk-
stratification remains difficult. Additional information that 
allows more detailed and precise stratification of patients 
into distinct prognostic groups would be valuable. Thus, 
novel biomarkers for reliably assessing individual patient’s 
risk of disease progression and outcome are highly needed.
Heat shock factor 1 (HSF1) is a ubiquitously 
expressed transcription factor that is crucial for cellular 
homeostasis and protection against protein damaging 
stress via the evolutionary conserved heat shock response. 
HSF1 also plays a vital role in tumor biology e.g. by 
promoting proliferation and survival upon oncogenic 
stimuli. Absence of HSF1 reduces proliferation and 
survival of human cancer cell lines, and protects mice 
from mutation- or carcinogen-driven tumors [8–13]. The 
tumorigenic property of HSF1 stems from activation of 
distinct transcriptional programs, including oncogenic 
support processes such as cell-cycle regulation, 
metabolism, adhesion, and translation, in both cancer 
cells and the tumor stroma. This demonstrates both 
cell-autonomous and non-cell-autonomous capabilities 
of HSF1 in orchestrating malignancy [14, 15]. Clinical 
relevance for HSF1 was demonstrated in breast, lung, 
and hepatocellular carcinoma where high mRNA and/
or protein expression correlates with poor prognosis 
[14–18]. Although we have demonstrated that HSF1 
promotes invasion in prostate cancer cell lines [19] and 
elevated expression has been detected in cancer cell lines 
and tumors [14, 19, 20], evidence for clinical significance 
of HSF1 in prostate cancer has not been demonstrated. 
Here, we explore the prognostic value of HSF1 in 
prostate cancer by analyzing independent mRNA gene 
expression datasets and two separate, large prostate cancer 
patient tissue microarray (TMA) cohorts: one radical 
prostatectomy cohort with extensive clinical information 
and long term follow-up (15.7 years) and a second separate 
cohort comprising of regionally advanced to distant 
metastatic tumors. Associations with clinical variables 
and disease outcomes were investigated using proportional 
hazards regression (univariate, multivariate and LASSO-
penalized Cox), binary decision tree model, Kaplan–
Meier estimates, and log-rank tests. We hypothesized that 
the expression status of HSF1 may be associated with 
progression and aggressiveness of prostate cancer and 
that HSF1 can be utilized for outcome prognostications of 
patients who have undergone radical prostatectomy.
rEsuLts
HSF1 mrnA is overexpressed in prostate cancer 
Since HSF1 has been demonstrated to be a strong 
promoter of oncogenesis, we hypothesized that HSF1 
would hold clinical significance in prostate cancer. 
Previously, we have noted elevated levels of HSF1 
mRNA when comparing human luminal prostate cancer 
cell lines to basal, benign prostate epithelial cell lines 
[19]. Thus, we first performed a large-scale analysis 
of HSF1 mRNA expression using all clinical prostate 
cancer datasets in cBioPortal (http://www.cbioportal.org/
public-portal) [21, 22] available at the time of analysis. 
This revealed high expression of HSF1 mRNA in tumor 
samples across all datasets when compared to matched 
normal samples (Figure 1A) [23–29]. In-depth analyses on 
the transcriptomics dataset from MSKCC [23], containing 
comprehensive prostate cancer profiles of 216 clinical 
samples from both primary tumors and metastases were 
then performed. Statistically significantly elevated HSF1 
levels were found to be associated with high grade group 
prostate cancer, positive lymph node status and metastasis 
(Figure 1B), all signs of progressing disease. Next, the 
association between mRNA expression and biochemical 
recurrence (BCR) was analyzed by stratifying the patients 
into high versus low HSF1 expressing groups. Interestingly, 
high HSF1 mRNA levels were associated with poor BCR-
free patient survival (p = 0.017; Figure 1C). These results 
imply clinical significance for HSF1 in advanced prostate 
cancer, and justify an in-depth analysis of HSF1 protein 
expression in large prostate cancer cohorts.
Increased HsF1 protein expression corresponds 
to advancement of prostate cancer
We pursued the clinical relevance of differential 
expression of HSF1 by immunohistochemistry (IHC) 
[30] on a large primary prostate cancer cohort of 
radical prostatectomy samples, collected into TMA I 
(Supplementary Table 1) [31, 32]. In the final analysis, 368 
patients had comprehensive clinical data and representative 
tissues in the TMA for analysis of HSF1. From each 
patient, three cores were obtained from the cancer areas 
and one core from an adjacent benign/normal area. HSF1 
was mainly detected in the nucleus, and the signal was 
scored as negative, weak, intermediate, or strong (score 
1–4, respectively; Figure 2A; Supplementary Figure 1). 
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Intriguingly, a clear majority (83%) of the prostate cancer 
cores showed intermediate to strong HSF1 expression, 
while 70% of the benign cores showed negative or 
weak HSF1 expression (Figure 2B). The association 
between HSF1 staining intensities and commonly used 
clinicopathological variables was further investigated 
by cross-tabulation and summary statistics (Table 1). 
This revealed that enhanced nuclear HSF1 expression 
was significantly associated with higher grade groups 
(p = 0.014), positive lymph node status (p = 0.017), and 
locally advanced (≥pT3) compared to organ-confined 
(pT2) disease (p = 0.003) (Figure 2C and 2D; Table 1). 
These results are in agreement with the increased HSF1 
mRNA levels detected in advanced prostate cancer and 
local metastases (Figure 1B).
Interestingly, in approximately 20% of the 
prostate cancer samples with HSF1 expression status, 
HSF1 was also detected in the cytoplasm, where it was 
scored as negative (no staining) or positive (Figure 2E; 
Supplementary Table 1; Supplementary Figure 2). The 
incidence of positive cytoplasmic staining increased with 
higher nuclear HSF1 expression score and grade group 
(Figure 2F–2G). 
strong HsF1 expression predicts risk of 
receiving secondary therapy
We assessed the connection between HSF1 
expression status and the likelihood of receiving secondary 
therapy after radical prostatectomy. Treatment decisions 
Figure 1: Analysis of HSF1 mrnA in large-scale transcriptomics datasets. (A) Expression status of HSF1 in all 
publicly available clinical prostate cancer studies containing mRNA expression data in the cBioPortal (http://www.cbioportal.org) 
shown as percentages of samples with altered mRNA expression in the respective study. z-score ± 2. Numbers in parentheses refer 
to the respective reference. TCGA, provisional: data generated by the TCGA Research Network: http://cancergenome.nih.gov/. 
(b) Analysis of HSF1 mRNA expression in a clinical prostate cancer dataset comprising of 216 samples [23] showing that HSF1 
expression is significantly increased in metastases, advanced prostate cancer (grade group 5), and lymph node invasion. The black 
line represents the median. Statistical significance was calculated using Mann-Whitney test. *P-values < 0.05; ***P-values < 0.001. 
SM: positive surgical margins; SV inv: seminal vesicle invasion. (c) Kaplan–Meier estimates of biochemical recurrence (BCR)-free 
survival in HSF1 mRNA expression groups, comparing 25% low-level expressing versus 75% high-level expressing prostate cancer 
tumors in the MSKCC dataset [23]. 
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Figure 2: Increased HsF1 protein expression corresponds to the progression of prostate cancer. (A) IHC staining of nuclear 
HSF1 protein on TMAs containing Gleason grade pattern 3–5 cores. Representative images are shown for negative (score 1), weak (score 
2), intermediate (score 3), and strong (score 4) HSF1 expression. Scale bar represents 100 µm. Blow-up images in the insets. GL, Gleason 
grade. (b) Nuclear HSF1 protein staining status (negative, weak, intermediate, strong) in benign/normal and malignant prostate cancer 
biopsies. (c) Association between nuclear HSF1 protein staining status and grade group (GG), demonstrating that increased expression 
correlates with high grade group tumors. (d) Comparison of samples from local (pT2) and locally advanced (≥pT3) disease showing 
statistically significantly higher levels of nuclear HSF1 in tumors that have spread outside the prostate. (E) IHC staining on TMAs, showing 
representative images with both nuclear and cytoplasmic positive HSF1 expression (left) and with positive nuclear expression but negative 
cytoplasmic HSF1 expression (right). Scale bar represents 100 µm. Blow-up images in the insets. (F) Cross-tabulation of nuclear and 
cytoplasmic HSF1 protein expression. N = number of patients. (G) Association between cytoplasmic HSF1 protein staining status and GG.
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for the patients were made by practicing urologists and 
reflect the clinical practice at the time. Analysis of the 
Kaplan–Meier estimates showed that strong nuclear 
HSF1 staining (score 4) was associated with shorter 
secondary therapy-free survival compared to low nuclear 
HSF1 staining (score 1–3) (Figure 3A, p = 0.033). 
Next, a univariate Cox regression model showed that 
strong nuclear HSF1 staining raised the risk of receiving 
secondary therapy with a hazard ratio (HR) of 1.56 (95% 
CI 1.03–2.35; p = 0.035) (Supplementary Table 2). When 
assessing the relationship between HSF1 and established 
clinical markers, a correlation matrix showed no marked 
dependencies (Supplementary Figure 3). In a multivariate 
Cox analysis that took established clinical markers into 
account, nuclear HSF1 staining remained an independent 
predictor of secondary therapy (HR 1.77; 95% CI 
1.03–3.02; p = 0.037) (Supplementary Table 2). 
Enhanced HsF1 expression correlates with poor 
disease-specific survival 
Next, we studied the relationship between HSF1 
expression and prostate cancer survival. In order to 
assess the utility of HSF1 as a prognostic marker further 
a competing risk analysis was performed where the 
probability to die specifically from prostate cancer, to 
die from other reasons, or to stay alive were compared 
in relation to the expression status of nuclear HSF1 
(Figure 3B). Interestingly, strong nuclear HSF1 expression 
clearly increased the likelihood to die from the disease 
(HR 2.55; 95% CI 1.10–5.94; p = 0.029). No evidence 
was found for HSF1 affecting the probability of dying 
for other reasons. To investigate the prognostic value of 
HSF1 in different patient groups and in relation to grade 
group on disease-specific survival, a survival decision tree 
was generated (Supplementary Figure 4A). The individual 
nuclear and cytoplasmic HSF1 scores as well as grade 
group were supplied as factors to the algorithm after 
which no further user interaction was required. Survival 
up to given time points in the patient groups derived by 
the tree is illustrated in Supplementary Figure 4B. The 
resulting tree revealed that while grade group remained 
the most informative prognostic factor (node 1), nuclear 
HSF1 expression status added to the survival prediction 
for advanced cancers (node 5; Supplementary Figure 4A). 
Simultaneously, the decision tree confirmed the division 
of nuclear HSF1 status used in analyses above, i.e. low 
(scores 1–3) vs strong (score 4) expression, as the most 
informative cut point (node 5). Cytoplasmic HSF1 
enhanced the prognostic value when the grade group was 
low (≤ 2; node 2). 
Kaplan–Meier graphs of disease-specific survival 
verified the findings by the tree model by showing that 
strong nuclear HSF1 expression predicted earlier patient 
table 1: Association between the level of nuclear and cytoplasmic HsF1 expression and tumor characteristics in tMA I
tumor characteristics
nuclear HsF1 score cytoplasmic HsF1 score
1–3 4 Pa negative Positive Pa
n (%) n (%) n (%) n (%)
Grade group 1 (4–6) 41 (58.6) 29 (41.4) 0.033 56 (81.2) 13 (18.8) 0.050
(Gleason score) 2 (3 + 4 = 7) 50 (57.5) 37 (42.5) 77 (86.5) 12 (13.5)
3 (4 + 3 = 7) 52 (46.4) 60 (53.6) 85 (75.9) 27 (24.1)
4 (8) 14 (32.6) 29 (67.4) 27 (64.3) 15 (35.7)
5 (9–10) 5 (38.5) 8 (61.5) 10 (71.4) 4 (28.6)
pT 2 101 (57.7) 74 (42.3) 0.003 143 (81.7) 33 (18.3) 0.16
≥3 55 (43.7) 71 (56.3) 95 (74.8) 32 (25.2)
Positive surgical Yes 29 (51.8) 27 (48.2) 1.00 50 (86.2) 8 (13.8) 0.12

























aP-values are calculated using the Fisher´s exact test for categorical variables and Wilcoxon test for continuous variables. 
bPSA is preoperative and values are mean.
Abbreviations: SD, standard deviation; PSA, prostate-specific antigen.
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death (p = 0.012; Figure 3C). At 10 years post-operation 
the likelihood of disease-specific survival was decreased 
by 8.4% (95% CI 2.8–14.0; Figure 3C). Disease-specific 
survival was not statistically significantly affected 
when stratifying patients by cytoplasmic HSF1 staining 
(Figure 3D). When combining nuclear and cytoplasmic 
HSF1 staining, patients with low nuclear expression (score 
1–3) and negative cytoplasmic HSF1 showed the longest 
disease-specific survival time compared to the other 
groups (Figure 3E). Cytoplasmic HSF1 also added to the 
prognostic value of the low-risk group with nuclear HSF1 
score 1–3 (Figure 3E, p = 0.023). 
HsF1 is a prognostic marker for prostate cancer-
specific death 
For prostate cancer-specific death, a univariate Cox 
proportional hazards model showed that strong nuclear 
HSF1 staining raised the risk with a HR of 2.62 (95% 
CI 1.21–5.67; p = 0.015; Table 2). When incorporating 
nuclear HSF1 together with grade group alone in a 
multivariate model, strong nuclear HSF1 remained 
an independent factor with a HR of 2.40 (95% CI 
1.06–5.41; p = 0.035; Table 2). This should be compared 
to the HR of GG, which was 1.78 (95% CI 1.28–2.48; 
p = 0.001). Possibly due to the small number of events 
(4.9% of the patients were deceased due to prostate 
cancer), the association with disease-specific survival did 
not reach statistical significance if additional variables 
were included into the model (Supplementary Table 3). 
To widen the range of clinical variables examined 
together with HSF1, we utilized the least absolute 
shrinkage and selection operator (LASSO)-regression 
model in combination with multiple imputation to 
account for missing values in the covariates. Four 
variables; pT ≥ 3, metastatic lymph node status, grade 
group 3 and 4–5, and strong HSF1 nuclear staining 
(score 4) were independently chosen by LASSO in 
over 75% of the imputed datasets suggesting that these 
hold independent prognostic value for disease-specific 
survival (Figure 3F). Further investigations on HSF1’s 
performance were assessed by the full clinical model 
CAPRA-S, which includes the variables PSA, GS in 
the radical prostatectomy specimen, surgical margin, 
seminal vesicle invasion, extracapsular extension, and 
lymph node invasion [33]. After demonstrating non-
dependency between HSF1 and CAPRA-S in an analysis 
of variance in which the average CAPRA-S scores did 
not differ statistically significantly between the nuclear 
HSF1 groups (F-test p = 0.221), multivariable analysis 
combined with multiple imputation was performed. 
This revealed a HR of 2.27 (95% CI 1.04–4.98) for a 
combined model with nuclear HSF1 and HR 1.27 (95% CI 
1.11–1.46) for CAPRA-S (Table 2). The average p-value 
from the imputed datasets in a subsequent likelihood-
ratio test comparing the joint model and the CAPRA-S 
score alone was 0.032, indicating that HSF1 brings added 
prognostic value on top of the CAPRA-S score. Taken 
together the results demonstrate that nuclear HSF1 is 
an independent prognostic marker from the currently 
established variables for guiding treatment decisions, and 
could potentially be used in clinical practice.
HsF1 is excessively expressed in advanced and 
metastatic tumors
Finally, to verify HSF1 stainings on TMAs and 
since HSF1 levels, both mRNA and protein, were found 
to increase with prostate cancer progression (Figure 
1B; Figure 2C; Table 1), we performed IHC on a large 
cohort from advanced prostate cancers (TMA II). This 
independent TMA contained 103 cores from the seminal 
vesicles and from metastases in the abdominal space, 
bladder, bone and local lymph nodes from 57 patients. 
Representative images from the seminal vesicles and 
metastatic sites showed HSF1 expression in infiltrating 
tumor cells (Figure 4A). Strikingly, intermediate or strong 
HSF1 nuclear expression was detected in the vast majority 
(93%) of the advanced cancer cores, and all except one 
of the cores simultaneously showed positive cytoplasmic 
HSF1 staining (Figure 4B–4C). The excessive amounts of 
both nuclear and cytoplasmic HSF1, independently of the 
metastatic site, highlight HSF1 as a key factor in invasion 
and metastasis of prostate cancer. 
dIscussIon
HSF1 is foremost known for mediating the heat 
shock response, a highly conserved mechanism that 
protects the cell from environmental and pathological 
proteotoxic damage [34]. In cancer, proteotoxic stress 
arises from various sources such as the heightened degree 
of aneuploidy, accumulation of mutated proteins and the 
harsh conditions of the tumor microenvironment [35, 36]. 
Not surprisingly, HSF1 expression has been found to be 
elevated in various cancer cell lines and cancer types and 
HSF1 identified as a driver of carcinogenesis [8, 10, 11]. 
It appears that cancer cells may hijack HSF1 functions 
and its transcriptional activity to promote survival, growth 
and metastatic propensity [13, 14]. While the oncogenic 
potential of HSF1 has been thoroughly demonstrated on 
a molecular level, its clinical significance has only begun 
to be revealed [14, 16]. We recently demonstrated that the 
absence of HSF1 renders prostate cancer cell lines in a 
non-differentiating acinar state, non-invasive, and prone 
to cell death in 3D organotypic cell culture. Likewise, 
in the chorioallantoic membrane in vivo model, tumors 
derived from prostate cancer cell lines showed reduced 
growth upon knock-down of HSF1 expression [19]. In this 
study a clinical significance of HSF1 in prostate cancer is 
demonstrated: increased HSF1 expression associates with 
disease progression and independently predicts initiation 
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of secondary therapy and poor disease-specific survival 
of prostate cancer patients after radical prostatectomy. 
This suggests that HSF1 could serve as a novel prognostic 
marker in prostate cancer. 
The prognostic value of HSF1 was here demonstrated 
using a comprehensive radical prostatectomy cohort 
with extensive follow-up time necessary for clinically 
relevant end points: initiation of secondary treatment and 
Figure 3: Elevated HsF1 expression predicts shorter time to secondary therapy and poorer disease-specific survival 
after radical prostatectomy. (A) Kaplan–Meier estimates of time to secondary therapy after radical prostatectomy showing low 
(score 1–3) versus strong (score 4) nuclear HSF1 staining, (b) Competing risk analysis where the probability to be in a specific state; alive 
(green), dead due to prostate cancer (red), and dead due to other reasons (blue), were estimated in relation to nuclear HSF1 expression, 
i.e. strong (score 4) versus low (score 1–3). (c–E) Kaplan–Meier estimates of disease-specific survival showing (C) strong (4) versus low 
(1–3) nuclear HSF1 staining, (D), negative or positive cytoplasmic HSF1 staining, or (E) combinations of nuclear and cytoplasmic HSF1 
staining. (F) Variables chosen by the LASSO-regression model combined with multiple imputation and with disease-specific survival as the 
end point. The covariates were tumor extension (pT), lymph node status, log preoperative PSA, GG, nuclear HSF1 staining, cytoplasmic 
HSF1 staining, and age at operation. Bright green indicates prognostic value; bright red indicates equivocal prognostic value; shades of 
grey indicate that no conclusions can be drawn from these data. N = number of patients.
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disease-specific survival. TMA I revealed that increased 
nuclear HSF1 expression is evident in malignant tissues 
and correlates with disease progression. Another 
independent TMA (TMA II), composed of prostate cancer 
in seminal vesicles or metastases, as well as the mining 
of publicly available mRNA datasets verified our findings 
of increased expression during disease advancement. 
In accordance, enhanced HSF1 mRNA expression has 
been detected in breast and hepatocellular carcinoma 
and enhanced nuclear HSF1 protein expression in a wide 
range of malignancies including hepatocellular carcinoma, 
breast, cervical, lung, pancreas, colon, and mesenchymal 
tumors [14, 16–18]. 
The clinical course of prostate cancer is highly variable 
and more accurate risk-stratification of patients is needed 
for informed therapeutic decision-making. One particular 
problem is the selection of individuals that are likely to 
benefit from locoregional and systemic treatment following 
radical prostatectomy of intermediate and high-risk patients. 
Despite extensive research to uncover reliable biomarkers 
that provide improved sensitivity over current tools, only 
three biomarkers are currently approved for clinical use by 
the US Food and Drug Administration (FDA): PSA, the 
related prostate health index that combines different PSA 
forms, and prostate cancer antigen 3 (PCA3), a long non-
coding RNA. A number of additional biomarkers, such as 
TMPRSS2-ERG gene fusion test and tests containing panels 
of markers, are offered as Clinical Laboratory Improvement 
Amendments-based laboratory developed tests. However, 
none of these has of yet been approved by the US FDA 
for clinical practice [37]. This study suggests that HSF1 
is a driver of prostate cancer progression and could serve 
as an informative biomarker for stratifying patients after 
radical prostatectomy. Strong nuclear HSF1 expression 
was, independently from established clinicopathological 
markers, associated with shorter time to secondary therapy. 
Importantly, strong nuclear HSF1 expression also predicted 
poor disease-specific survival, demonstrating HSF1 as a 
determinant of lethal disease. Of note, the prognostic HR 
values derived from HSF1 nuclear scores were comparable to 
those derived from common established clinical markers such 
as GG. In addition, independence from the full clinical model 
CAPRA-S, as demonstrated by variance analysis, allowed a 
combined risk analysis after multiple imputation. Subsequent 
likelihood-ratio test demonstrated the value of nuclear HSF1 
in the model for predicting disease-specific survival. 
Although the size and follow-up time of the patient 
cohorts used in this study were substantial and enabled 
pertinent end point analyses, the relatively low count of 
lethal events reduced the statistical power in subgroup 
and multivariate models. For these reasons, a multivariate 
Cox analysis of disease-specific survival was of only 
limited use. However, by utilizing LASSO-penalization 
and applying multiple imputation, these shortages were 
addressed and the prognostic value of HSF1 shown. 
Specifically, the joint analysis with the established 
CAPRA-S score with subsequent likelihood-ratio test 
verified HSF1 as an independent and relevant marker. 
Prospective studies on extensive, independent cohorts are 
however warranted to estimate the magnitude of the effect.
This study is based on samples taken after radical 
prostatectomy or at an advanced stage. For subsequent 
table 2: univariate and multivariate cox proportional hazards models on disease-specific survival in prostate cancers
univariate
disease-specific survival
Hr 95% cI P
HSF1 nuclear (score 4 vs 1–3) 2.62 1.21–5.67 0.015
HSF1 cytoplasmic (positive vs negative) 1.91 0.90–4.04 0.091
Grade group 1.88 1.38–2.56 <0.001
pT (≥T3 vs T2) 12.85 3.86–42.82 <0.001
PSA 1.03 1.01–1.05 0.011
Positive surgical margin 0.62 0.22–1.77 0.37
Lymph node metastasis 5.05 1.75–14.55 <0.001
Multivariatea HR 95% CI P
HSF1 nuclear (score 4 vs 1–3) 2.40 1.06–5.41 0.035
Grade group 1.78 1.28–2.48 0.001
Multivariate + MI HR 95% CI
CAPRA-S 1.27 1.11–1.46
HSF1 nuclear 2.27 1.04–4.98
aNumber of patients, 324; number of events, 31.
Abbreviations: CI, confidence interval; HR, hazard ratio; MI, multiple imputation.
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IHC analyses, HSF1 status could be surveyed in biopsies 
and connected to disease outcome for a prognostic value 
on progression and disease-specific survival, possibly 
saving patients from unnecessary radical prostatectomy 
and aiding earlier treatment. Although IHC is an 
indispensable technique in pathology laboratories, varying 
staining quality can pose a problem. However, potential 
problems can be overcome by following published 
guidelines on standardization [38, 39]. These include the 
use of an antigen retrieval method that enables detection 
from formalin-fixed and paraffin-embedded surgical 
specimens, automated staining, and digital pathology 
combined with imaging analysis. Furthermore, thorough 
antibody testing, optimization, and validation, including 
the use of positive and negative controls, is a prerequisite. 
In order to use HSF1 IHC analyses as an established 
method in clinics in the future, a standard operating 
procedure protocol should be developed. 
Apart from the prognostic value, our findings 
hold therapeutic potential. HSF1 has been considered a 
target for anti-cancer therapy due to the dependency of 
malignancies on this non-oncogene and its overexpression 
in many cancers [40]. Several small molecular inhibitors 
of HSF1 have been identified [40, 41], and a water-
soluble pro-drug of the inhibitor triptolide is currently in 
phase I clinical trial for advanced gastrointestinal tumors 
(NTCT01927965) and has demonstrated pre-clinical 
activity against hepatocellular carcinoma, osteosarcoma, 
and ovarian and pancreatic cancer [42–44]. Our results on 
differential expression of HSF1 open up for therapeutic 
interventions also in prostate cancer. 
In conclusion, this study enhances the understanding 
of prostate cancer progression by demonstrating that the 
levels of HSF1 increases as the disease advances and that 
HSF1 status predicts disease-specific survival. Taken 
together, the study demonstrates that characterizing HSF1 
expression with straight-forward and robust antibody-
based detection holds potential for use in clinical practice, 
i.e. for risk-stratification and outcome predictions of 
patients treated with radical prostatectomy.
MAtErIALs And MEtHods
study design 
Reporting recommendations for tumor marker 
prognostic studies; REMARK [45] was followed 
throughout the study. The study design is outlined in 
Supplementary Figure 5.
bioinformatics of mrnA expression in clinical 
samples
Expression status of HSF1 was investigated in all 
clinical prostate cancer studies available at the time of 
analysis through the cBioPortal for Cancer Genomics 
Figure 4: HsF1 protein expression in samples from regionally advanced to distant metastatic sites of prostate cancer. 
(A) IHC stainings of HSF1 on TMA II containing samples from the abdominal space (Ab), bladder (Bl), bone (Bo), iliac lymph node (LN), 
and seminal vesicle (SV). Scale bar represents 100 µm. Blow-ups in the insets. (b) Distribution of nuclear HSF1 intensity at the different 
sites. (c) Cross-tabulation of the level of nuclear and cytoplasmic HSF1 expression in the samples. (B–C) The numbers designate patients.
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(http://www.cbioportal.org/public-portal) [21, 22]. For in-
depth analysis, a clinical transcriptome study (Memorial 
Sloan Kettering Cancer Centre, MSKCC) [23] was used, 
containing 216 prostate cancer samples and metastases 
with comprehensive profiles, of which 85 displayed 
complete mRNA, copy number, sequencing data, and 
based on Affymetrix Human Exon 1.0 ST Arrays and next-
generation sequencing. Gene expression data from curated 
and normalized values were analyzed in GeneSapiens 
[46]. Normalized raw expression data of the MSKCC 
collection was extracted, median centered, and analyzed 
through an in-house HTML interface, REX, which houses 
a collection of relevant R-scripts for mining of data and 
plotting of observations. Associations of gene expression 
with clinical annotations (e.g. grade group, invasion 
status) were processed with R. 
clinical prostate cancer samples for tissue 
microarrays
Prostate cancer specimens from two independent 
clinical cohorts were constructed into TMA I and II. For 
TMA I, samples were obtained from 478 patients treated 
by radical prostatectomy during the years 1982–1998 
at Helsinki University Hospital, Finland. For the final 
analysis, 368 patients without neoadjuvant treatment 
and with comprehensive data, HSF1 expression status, 
and tissue material available were included. Clinical 
preoperative and follow-up information including overall 
and disease-specific mortality data was gathered from the 
Finnish Cancer Registry, and updated in November 2015. 
The age of the patients at diagnosis ranged between 45 
and 76 years, and none had received adjuvant therapy 
before or immediately after surgery. The median post-
surgery follow-up time was 15.7 years (Supplementary 
Table 1). For TMA II, 103 samples from regionally 
advanced and distant metastatic sites of 62 patients treated 
at Turku University Hospital, Finland between 1993 and 
2008, were used [47]. In the final analysis, cores from 
57 samples were representative for scoring, including 1 
abdominal, 2 bladder, 7 bone, 31 lymph node metastases 
and 16 seminal vesicle infiltration samples. The median 
age of the patients was 64 years, and some had received 
hormonal treatments. For both TMAs, histopathological 
features were independently reviewed by pathologists 
using hematoxylin-eosin or Herovici’s collagen stained 
slides. Sample and clinicopathological data usage was 
approved by the ethics committees of Hospital District of 
Helsinki or Uusimaa and Hospital District of Southwest 
Finland, and the National Authority for Welfare and 
Health in Finland according to national legislation. Use 
of the Finnish Cancer Registry’s data was approved by the 
National Institute for Health and Welfare. Patient data was 
de-identified prior to analyses. 
construction of the tMAs and 
immunohistochemistry 
The TMAs were constructed using archival 
formalin-fixed, paraffin-embedded blocks as described in 
[32]. For TMA I, the blocks from each patient were drilled 
from different areas to account for tumor heterogeneity: 
two cores from the area containing the most dominant 
Gleason grade pattern, one core form the area containing 
the second most dominant Gleason pattern, and one 
core from an adjacent benign glandular area. TMA I, 
comprising prostate cancer prostatectomy samples, 
contained a total of 1758 cores. TMA II, comprising 
disseminated prostate cancer samples, contained a total 
of 105 cores from regional and distant sites. All cancer 
cores were scored individually, according to the Gleason 
grade pattern. Freshly cut 4 µM thick TMA sections were 
mounted on electrically charged glass slides (SuperFrost 
Plus, Menzel-Gläser, Braunschweig, Germany), and 
stained using Lab Vision™ PT Module and Autostainer 
480 (Thermo Scientific, Waltham, MA, USA) with heat-
induced epitope retrieval in TRIS buffer. The slides 
were incubated with rabbit polyclonal HSF1 antiserum 
(1:1000), generated and described previously [30]. 
Shortly, purified 65–70 kDa recombinant human HSF1 
was used for immunization of rabbits. Specificity was 
verified by Western blotting using recombinant human 
HSF1 and human cell lysates [30]. For the TMA, HSF1 
staining of normal, human urinary bladder tissue was 
used as a positive control, showing consistency with 
stainings in Protein Atlas (https://www.proteinatlas.org/
ENSG00000185122-HSF1/tissue). Rabbit IgG staining 
of prostate cancer tissue was used as a negative antibody 
control (Supplementary Figure 1).
digitalization and scoring of tMA cores
The TMAs were analyzed largely as described by 
Björkman et al., 2012 [32]. The immunostained TMA 
sections were digitized with an automated whole slide 
scanner (Mirax Scan, Zeiss, Göttingen, Germany) and 
virtual slides were uploaded to a web server (http://
fimm.webmicroscope.net). Reliable Gleason grading 
was possible for 1064 out of 1104 prostate cancer TMA 
I cores stained with HSF1 antibody. HSF1 expression 
was evaluated by a pathologist (TM) independently from 
the digitized slides without information on grade and 
clinicopathological data. In all analyses, the maximum 
HSF1 score of the available prostate cancer cores for 
each individual patient was used. The nuclear staining 
intensity was scored as: no staining (negative, score 1), 
weak (score 2), intermediate (score 3), or high (score 4), 
and the cytoplasmic staining was scored as: no staining 
(negative) or positive. To assess the reliability of the HSF1 
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measurements, the correlation structure of the scores 
was investigated (Supplementary Figure 6). In short, 
little or no dependency was found between scores from 
differing sources, while scores from the same source were 
moderately correlated (Spearman r = 0.57–0.66). This level 
of agreement can be considered satisfactory, however, low 
enough to justify multiple samples from each patient.
statistical analysis
Associations between categorical variables were 
investigated by cross-tabulation and Fisher’s exact test. 
Differences in average values of continuous variables 
between factor groups were assessed with non-parametric 
Wilcoxon signed-rank test. Survival analyses were 
performed with Kaplan–Meier estimates and log-rank 
tests. HRs were obtained by fitting Cox proportional 
hazards regression models for single and multiple 
prognostic factors. Correlations between variables were 
estimated using the non-parametric Spearman’s rank 
correlation.
A binary decision tree [48] was utilized to provide 
an automated approach to deriving useful prognostic 
groups. In contrast to the Cox models using only the 
main effects of the variables, this approach makes 
minimal assumptions on the structure of the data and is 
able to detect possible interactions between covariates 
and nonlinear dependencies. The tree was constructed by 
consecutively splitting the patients into groups at points 
that minimize the log-rank test p-value. The splitting point 
is chosen among all covariates supplied to the algorithm. 
The method can thus also be used for identifying useful 
prognostic factors. 
Least absolute shrinkage and selection operator 
(LASSO)-penalized Cox regression [49] was used for 
picking the most relevant variables among a large set 
of prognostic factors. The method aims to set the HR 
related to unnecessary prognostic factors to exactly 1, thus 
negating their effect in the model. The method is controlled 
by a hyperparameter λ, whose value was chosen using 
5-fold cross-validation [50]. 
Multiple imputation [51] was used to address the 
missing values of variables other than HSF1 expression 
in the data. The method imputes any missing data with 
reasonable guesses by taking into account the (non-missing) 
values in the other variables. The guesses are random, and 
thus to characterize the full uncertainty in the missing 
value estimation, the procedure is repeated multiple times. 
This results in a set of imputed datasets that differ in their 
imputed missing values. The subsequent analyses are 
then performed on each of the datasets and the results are 
combined for the final analysis using Rubin’s rules [52]. 
Multivariate analyses with Cancer of the Prostate 
Risk Assessment post-Surgical (CAPRA-S) score were 
performed as detailed in [33]. In an analysis of variance, 
the average CAPRA-S scores did not differ statistically 
significantly between the nuclear HSF1 groups (F test 
p = 0.221) demonstrating non-dependency between 
HSF1 and CAPRA-S. Missing values in the data set were 
handled by multiple imputation, however no HSF1 data 
was imputed. 100 imputed datasets were created with 
varying imputed values reflecting the uncertainty of the 
imputation. The Cox model was fitted on each of the 
imputed datasets and collected into a single analysis. The 
variation between the imputed datasets was significantly 
smaller than the average estimation uncertainty for 
disease-specific survival (Supplementary Table 4). 
From these data, confidence intervals for the HRs were 
constructed using Rubin’s rules. 
All statistical analyses were performed with the 
programming language R, version 3.2 (R Foundation 
for Statistical Computing, http://www.R-project.org). 
Nonstandard external R-packages used include glmnet 
[53], ggplot2 [54], mi [55], riskRegression (https://
CRAN.R-project.org/package=riskRegression) and rpart 
(https://CRAN.R-project.org/package=rpart).
Abbreviations
BCR: biochemical recurrence; CAPRA-S: Cancer 
of the Prostate Risk Assessment post-Surgical; GG: grade 
group; GL: Gleason grade; HSF1: heat shock factor 1; HR: 
hazard ratio; IHC: immunohistochemistry; LASSO: least 
absolute shrinkage and selection operator; PSA: prostate-
specific antigen; TMA: tissue microarray.
Author contributions
Conception and design of the experiments: JKB, 
MÅ, MN, TM. Acquisition of data: AB, SN, TM. 
Analysis and interpretation of data: IA, JKB, MÅ, TM. 
Statistical analysis: IA. Writing of the manuscript: JKB. 
Administrative, technical, or material support: AB, AE, 
AR, JL, LS, ML, MN, SN, TM. All authors have reviewed 
and validated the manuscript.
AcKnoWLEdGMEnts 
Paula Vainio is acknowledged for valuable help in 
data collection (TMA II) and Tiina Vesterinen for IHC 
stainings.
conFLIcts oF IntErEst
The authors declare that they have no conflicts of 
interest.
FundInG
This work was supported by the Academy of 
Finland (265918 (JKB), 267326 (MN), 268531 (TM)), 
Oncotarget31211www.oncotarget.com
Finnish Medical Foundation (TM) and Cancer Society 
Finland (TM). The authors confirm that the funder had no 
influence over the study design, content of the article, or 
selection of journal.
rEFErEncEs
 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers 
C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer 
incidence and mortality worldwide: sources, methods and 
major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 
136:E359–86.
 2. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, 
Banerjee M, Pontes JE, Wood DP Jr. Should Gleason score 
7 prostate cancer be considered a unique grade category. 
Urology. 1999; 53:372–377.
 3. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, 
Zincke H. Prognostic factors for survival of patients with 
pathological Gleason score 7 prostate cancer: differences in 
outcome between primary Gleason grades 3 and 4. J Urol. 
2001; 166:1692–1697.
 4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, 
Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli 
I, Iyer P, Cartagena R, et al. Radical prostatectomy versus 
observation for localized prostate cancer. N Engl J Med. 
2012; 367:203–213.
 5. Shen MM, Abate-Shen C. Molecular genetics of prostate 
cancer: new prospects for old challenges. Genes Dev. 2010; 
24:1967–2000.
 6. Schoenborn JR, Nelson P, Fang M. Genomic profiling 
defines subtypes of prostate cancer with the potential 
for therapeutic stratification. Clin Cancer Res. 2013; 
19:4058–4066.
 7. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, 
Humphrey PA; Grading Committee. The 2014 International 
Society of Urological Pathology (ISUP) Consensus 
Conference on Gleason Grading of Prostatic Carcinoma: 
Definition of Grading Patterns and Proposal for a New 
Grading System. Am J Surg Pathol. 2016; 40:244–252.
 8. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat 
shock factor 1 is a powerful multifaceted modifier of 
carcinogenesis. Cell. 2007; 130:1005–1018.
 9. Min JN, Huang L, Zimonjic DB, Moskophidis D, Mivechi 
NF. Selective suppression of lymphomas by functional loss 
of Hsf1 in a p53-deficient mouse model for spontaneous 
tumors. Oncogene. 2007; 26:5086–5097.
10. Jin X, Moskophidis D, Mivechi NF. Heat shock transcription 
factor 1 is a key determinant of HCC development by 
regulating hepatic steatosis and metabolic syndrome. Cell 
Metab. 2011; 14:91–103.
11. Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal 
S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron 
LA, Perry SR, Zeid R, et al. Proinvasion metastasis drivers 
in early-stage melanoma are oncogenes. Cancer Cell. 2011; 
20:92–103.
12. Xi C, Hu Y, Buckhaults P, Moskophidis D, Mivechi NF. 
Heat Shock Factor Hsf1 Cooperates with ErbB2 (Her2/Neu) 
to Promote Mammary Tumorigenesis and Metastasis. J Biol 
Chem. 2012; 287:35646–35657.
13. Vihervaara A, Sistonen L. HSF1 at a glance. J Cell Sci. 
2014; 127:261–266.
14. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, 
Tamimi RM, Fraenkel E, Ince TA, Whitesell L, Lindquist 
S. HSF1 Drives a Transcriptional Program Distinct from 
Heat Shock to Support Highly Malignant Human Cancers. 
Cell. 2012; 150:549–562.
15. Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, 
Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, 
Stemmer SM, Whitesell L, Lindquist S. The reprogramming 
of tumor stroma by HSF1 is a potent enabler of malignancy. 
Cell. 2014; 158:564–578.
16. Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, 
Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, 
Lindquist S, Ince TA. High levels of nuclear heat-shock 
factor 1 (HSF1) are associated with poor prognosis in breast 
cancer. Proc Natl Acad Sci U S A. 2011; 108:18378–18383.
17. Fang F, Chang R, Yang L. Heat shock factor 1 promotes 
invasion and metastasis of hepatocellular carcinoma in vitro 
and in vivo. Cancer. 2012; 118:1782–1794.
18. Gokmen-Polar Y, Badve S. Upregulation of HSF1 in 
estrogen receptor positive breast cancer. Oncotarget. 2016; 
7:84239–84245. https://doi.org/10.18632/oncotarget.12438.
19. Björk JK, Åkerfelt M, Joutsen J, Puustinen MC, Cheng F, 
Sistonen L, Nees M. Heat-shock factor 2 is a suppressor of 
prostate cancer invasion. Oncogene. 2016; 35:1770–1784.
20. Hoang AT, Huang J, Rudra-Ganguly N, Zheng J, Powell 
WC, Rabindran SK, Wu C, Roy-Burman P. A novel 
association between the human heat shock transcription 
factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol. 
2000; 156:857–864.
21. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy 
BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin 
Y, Reva B, Goldberg AP, et al. The cBio cancer genomics 
portal: an open platform for exploring multidimensional 
cancer genomics data. Cancer Discov. 2012; 2:401–404.
22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, 
Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami 
E, Sander C, Schultz N. Integrative analysis of complex 
cancer genomics and clinical profiles using the cBioPortal. 
Sci Signal. 2013; 6:l1.
23. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao 
Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, 
Antipin Y, Mitsiades N, Landers T, et al. Integrative 
genomic profiling of human prostate cancer. Cancer Cell. 
2010; 18:11–22.
24. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, 
Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen 
E, Stransky N, Nickerson E, Chae SS, Boysen G, et al. 
Exome sequencing identifies recurrent SPOP, FOXA1 and 
Oncotarget31212www.oncotarget.com
MED12 mutations in prostate cancer. Nat Genet. 2012; 
44:685–689.
25. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran 
SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, 
Asangani IA, Ateeq B, Chun SY, et al. The mutational 
landscape of lethal castration-resistant prostate cancer. 
Nature. 2012; 487:239–243.
26. Cancer Genome Atlas Research Network. The Molecular 
Taxonomy of Primary Prostate Cancer. Cell. 2015; 
163:1011–1025.
27. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro 
RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard 
CC, Attard G, Beltran H, Abida W, Bradley RK, et al. 
Integrative clinical genomics of advanced prostate cancer. 
Cell. 2015; 161:1215–1228.
28. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca 
L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi 
BV, Varambally S, Tomlins SA, Nanus DM, Tagawa 
ST, et al. Divergent clonal evolution of castration-
resistant neuroendocrine prostate cancer. Nat Med. 2016; 
22:298–305.
29. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, 
Gulati R, Etzioni R, Bolouri H, Montgomery B, White 
T, Lucas JM, Brown LG, Dumpit RF, et al. Substantial 
interindividual and limited intraindividual genomic 
diversity among tumors from men with metastatic prostate 
cancer. Nat Med. 2016; 22:369–378.
30. Holmberg CI, Illman SA, Kallio M, Mikhailov A, Sistonen 
L. Formation of nuclear HSF1 granules varies depending on 
stress stimuli. Cell Stress Chaperones. 2000; 5:219–228.
31. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, 
Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, 
Vesterinen T, Nordling S, Kallioniemi O, et al. Dual role 
of FoxA1 in androgen receptor binding to chromatin, 
androgen signalling and prostate cancer. EMBO J. 2011; 
30:3962–3976.
32. Björkman M, Östling P, Härmä V, Virtanen J, Mpindi JP, 
Rantala J, Mirtti T, Vesterinen T, Lundin M, Sankila A, 
Rannikko A, Kaivanto E, Kohonen P, et al. Systematic 
knockdown of epigenetic enzymes identifies a novel histone 
demethylase PHF8 overexpressed in prostate cancer with 
an impact on cell proliferation, migration and invasion. 
Oncogene. 2012; 31:3444–3456.
33. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S 
score: A straightforward tool for improved prediction 
of outcomes after radical prostatectomy. Cancer. 2011; 
117:5039–5046.
34. Åkerfelt M, Morimoto RI, Sistonen L. Heat shock factors: 
integrators of cell stress, development and lifespan. Nat Rev 
Mol Cell Biol. 2010; 11:545–555.
35. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction 
and the stress phenotype of cancer cells. Cell. 2007; 
130:986–988.
36. Luo J, Solimini NL, Elledge SJ. Principles of cancer 
therapy: oncogene and non-oncogene addiction. Cell. 2009; 
136:823–837.
37. Saini S. PSA and beyond: alternative prostate cancer 
biomarkers. Cell Oncol. 2016; 39:97–106.
38. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG; 
Members of Ad-Hoc Committee On Immunohistochemistry 
Standardization. Recommendations for improved 
standardization of immunohistochemistry. Appl 
Immunohistochem Mol Morphol. 2007; 15:124–133.
39. Lin F, Chen Z. Standardization of diagnostic 
immunohistochemistry: literature review and geisinger 
experience. Arch Pathol Lab Med. 2014; 138:1564–1577.
40. Whitesell L, Lindquist S. Inhibiting the transcription factor 
HSF1 as an anticancer strategy. Expert Opin Ther Targets. 
2009; 13:469–478.
41. Moore CL, Dewal MB, Nekongo EE, Santiago S, Lu 
NB, Levine SS, Shoulders MD. Transportable, Chemical 
Genetic Methodology for the Small Molecule-Mediated 
Inhibition of Heat Shock Factor 1. ACS Chem Biol. 2016; 
11:200–210.
42. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. 
Triptolide, an inhibitor of the human heat shock response 
that enhances stress-induced cell death. J Biol Chem. 2006; 
281:9616–9622.
43. Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, 
Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers 
SM, Saluja AK. A preclinical evaluation of Minnelide as a 
therapeutic agent against pancreatic cancer. Sci Transl Med. 
2012; 4:156ra139.
44. Banerjee S, Thayanithy V, Sangwan V, Mackenzie TN, 
Saluja AK, Subramanian S. Minnelide reduces tumor 
burden in preclinical models of osteosarcoma. Cancer Lett. 
2013; 335:412–420.
45. McShane LM, Altman DG, Sauerbrei W, Taube SE, 
Gion M, Clark GM; Statistics Subcommittee of the NCI-
EORTC Working Group on Cancer Diagnostics. REporting 
recommendations for tumour MARKer prognostic studies 
(REMARK). Br J Cancer. 2005; 93:387–391.
46. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, 
Pisto T, Saarela M, Skotheim RI, Björkman M, Mpindi JP, 
Haapa-Paananen S, Vainio P, et al. Systematic bioinformatic 
analysis of expression levels of 17,330 human genes across 
9,783 samples from 175 types of healthy and pathological 
tissues. Genome Biol. 2008; 9:R139.
47. Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen 
P, Fey V, Perala M, Smit F, Verhaegh G, Schalken J, Alanen 
KA, Kallioniemi O, et al. Arachidonic acid pathway 
members PLA2G7, HPGD, EPHX2, and CYP4F8 identified 
as putative novel therapeutic targets in prostate cancer. Am 
J Pathol. 2011; 178:525–536.
48. Strobl C, Malley J, Tutz G. An introduction to recursive 
partitioning: rationale, application, and characteristics of 
Oncotarget31213www.oncotarget.com
classification and regression trees, bagging, and random 
forests. Psychol Methods. 2009; 14:323–348.
49. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization 
Paths for Cox’s Proportional Hazards Model via Coordinate 
Descent. J Stat Softw. 2011; 39:1–13.
50. Arlot S, Celisse A. A survey of cross-validation procedures 
for model selection. Statistics Surveys. 2010; 4:40–79.
51. Raghunathan TE, Lepkowski JM, Van Hoewyk J, 
Solenberger P. A Multivariate Technique for Multiply 
Imputing Missing Values Using a Sequence of Regression 
Models. Surv Methodol. 2001; 27:85–95.
52. Rubin D. Multiple Imputation for Nonresponse in Surveys. 
John Wiley & Sons. New York. 1987.
53. Friedman J, Hastie T, Tibshirani R. Regularization Paths for 
Generalized Linear Models via Coordinate Descent. J Stat 
Softw. 2010; 33:1–22.
54. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 
Springer-Verlag. New York. 2009.
55. Su Y, Gelman A, Hill J, Yajima M. Multiple Imputation with 
Diagnostics (mi) in R: Opening Windows into the Black 
Box. J Stat Softw. 2011; 45:1–31.
